Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies.

RSS de esta página

PubMed ID: 29789015

Imagen Publicación

Panebianco C, Andriulli A, Pazienza V

Microbiome. 05 2018. doi: 10.1186/s40168-018-0483-7

COMMENT: There is a growing evidence of the importance of the microbiome not only in the development and outcome of certain kind of cancers but also in the patient response to chemo and immunotherapy. Besides, anticancer treatments are known to affect the patient gut microbiome. The authors review in this review article the current state of the art of what is known about the complex interactions between patient microbiome (gut and intratumor microbiome) and anticancer therapies: mainly chemo and immunotherapy.

Given the evidence that the microbiome can affect the efficacy of the anticancer therapies the authors also review the possibility of manipulate gut microbiome to improve the patient outcome. Particularly the use of probiotics, probiotics, antibiotics, synbiotics and postbiotics.


Marina Manrique